Biopharma Deal Tracker 2026
Every M&A, licensing, and partnership deal across life sciences — tracked, benchmarked, and analyzed. 1,600+ verified transactions. 12 therapeutic areas. Real-time coverage.
1,600+
Verified Deals
M&A, licensing, partnerships
12
Therapeutic Areas
Oncology to rare disease
23+
Modalities Tracked
ADCs, CAR-T, gene therapy, mAbs
Daily
Update Frequency
SEC, FTC, press releases
Market Overview
2026 Deal Landscape
The biopharma transaction market is on pace for a record year. Here is what the data shows through H1 2026.
$134B+
Total Deal Value, H1 2026
Aggregate disclosed value across M&A, licensing, and partnerships in the first half of 2026 — surpassing full-year 2024 totals.
33
Acquisitions Over $1B
Large-cap pharma is deploying cash aggressively. Oncology and immunology dominate mega-deal activity, with obesity/metabolic a close third.
Record
Deal Pace
Transaction volume is up 28% year-over-year. Patent cliffs, IRA pricing pressure, and GLP-1 competition are accelerating dealmaking across the sector.
Weekly deal intelligence in your inbox
Market Pulse delivers the week's most significant transactions, benchmark shifts, and strategic analysis every Monday.
Beyond Aggregation
Not just a deal list. A deal intelligence platform.
Generic trackers catalog transactions. Solidus tells you what they mean — quantitatively. Every deal is benchmarked, valued, and analyzed with the same rigor a top-tier advisory desk applies to live mandates.
Deal Benchmarking
Every transaction is benchmarked against comparable deals by phase, modality, therapeutic area, and deal structure. Know instantly where a deal falls relative to market norms.
rNPV Modeling
Risk-adjusted net present value calculations calibrated to phase-specific success probabilities, development timelines, and market assumptions. Not back-of-envelope math — real financial modeling.
Monte Carlo Simulation
10,000-iteration stochastic simulation across every material variable — approval probability, market size, competitive dynamics, pricing erosion. Probability distributions, not point estimates.
Pharma Intent Score
Proprietary 10-factor scoring system that tracks acquirer behavior signals — clinical investments, hiring patterns, conference activity, pipeline gaps — to surface which pharma companies are most likely to transact next.
Deal Structure Analysis
Milestone waterfall decomposition, royalty tier modeling, territory economics, and option exercise analysis. Understand not just total deal value, but how value is structured and when it realizes.
Competitive Dynamics
Track how competitive landscape shifts affect deal terms. See how new entrants, regulatory decisions, and clinical readouts in adjacent programs reprice comparable assets in real time.
Coverage
12 Therapeutic Areas. Full Deal Coverage.
From blockbuster oncology acquisitions to rare disease licensing, Solidus tracks deal activity across every major therapeutic category in biopharma.
Getting Started
From deal search to board-ready analysis in minutes
01
Search & filter
Find deals by therapeutic area, modality, phase, deal type, value range, or company. Browse the full database or zero in on your competitive set.
Open Calculator02
Benchmark & compare
Every result includes percentile positioning, comparable deals, and benchmark ranges for upfronts, milestones, and royalties. Context, not just data.
View Benchmarks03
Model & present
Run rNPV, Monte Carlo, and scenario analysis. Generate deal memos and negotiation playbooks. Export board-ready reports.
Explore CompaniesBuilt For
The deal intelligence layer for biopharma professionals
Business Development & Licensing
Benchmark your deal terms against market. Identify the right partners. Build data-backed negotiation positions instead of relying on anecdote and instinct.
Corporate Development & M&A
Screen acquisition targets with real comparable transaction data. Model deal economics with phase-adjusted rNPV and Monte Carlo simulation before term sheets go out.
Venture Capital & Investment
Evaluate portfolio company licensing potential. Size exit scenarios against verified deal comps. Track competitor deal activity across your thesis areas.
Strategy & Consulting
Arm client presentations with current, verified deal data. Build competitive landscape analyses that reference actual transaction terms, not estimates.
FAQ
Frequently Asked Questions
How many deals does the Solidus tracker cover?
Solidus tracks 1,600+ verified biopharma transactions spanning licensing agreements, acquisitions, collaborations, option deals, and co-development partnerships. The database covers deals from 2011 to present, with comprehensive coverage of 2024-2026 activity across 12 therapeutic areas.
How often is the deal data updated?
The Solidus deal database is updated daily. New transactions are sourced from SEC 8-K filings, FTC premerger notifications, company press releases, and regulatory databases. Each deal is verified and standardized before inclusion, ensuring consistent, comparable data across the entire database.
What deal types are tracked?
Solidus tracks five primary deal types: licensing agreements (exclusive and co-exclusive), acquisitions (full and asset purchases), research collaborations, option agreements, and co-development partnerships. Each deal record includes upfront payments, milestone structures, royalty rates, territory scope, and development obligations where disclosed.
How is Solidus different from DealForma or Cortellis?
Solidus goes beyond deal aggregation. Every transaction in the database is benchmarked against comparable deals, with quantitative analysis including rNPV modeling, Monte Carlo simulation (10,000 iterations), and Pharma Intent Score tracking. While platforms like DealForma and Cortellis catalog deals, Solidus provides the analytical layer — what a deal is worth, how it compares, and what it signals about partner strategy.
Is the tracker free?
Yes. The core deal tracker and calculator are free to use with no account required. Free access includes deal browsing, basic benchmarking across all 12 therapeutic areas, and company profiles. Pro subscribers unlock rNPV modeling, Monte Carlo simulation, AI deal memos, comparable deal analysis, and full negotiation playbooks.
Advisory Services
Need deal-level advisory, not just data?
Ambrosia Ventures provides hands-on M&A and licensing advisory for biotech companies navigating complex transactions. The same team and data behind Solidus, applied directly to your deal.
About the Solidus Biopharma Deal Tracker
The Solidus biopharma deal tracker is built and maintained by Ambrosia Ventures, a life sciences M&A advisory firm. Unlike passive deal databases, Solidus applies quantitative analysis to every transaction — risk-adjusted valuation, stochastic simulation, and competitive benchmarking — using the same frameworks applied in live advisory mandates.
The database currently contains 1,600+ verified biopharma deals across 12 therapeutic areas — licensing, acquisitions, collaborations, option agreements, and co-development — sourced from SEC 8-K filings, FTC premerger filings, press releases, and regulatory databases. Coverage spans 2011 to present with comprehensive indexing of 2024-2026 transaction activity.
For professionals evaluating licensing opportunities, assessing acquisition targets, or building competitive intelligence, Solidus provides the analytical depth that generic deal aggregators lack. Explore the deal benchmarks, run a custom analysis, or browse 700+ company profiles.